Latest Tokyo Brief coverage on KYORIN Pharmaceutical Co., Ltd., tracking filings, financial news, and market signals from Japan.
TSE:4569
Kyorin Pharmaceutical has signed to sell its generics subsidiary, including the Takaoka and Inami plants, to a venture owned by Daito, Meiji Seika Pharma and DBJ, with closing planned for April 1, 2027 and authorized generics carved out.
SUSMED began selling its Medcle insomnia app on 1 June, but the year to June 2026 rested on ¥340mn of partner milestones, ended with a ¥382.7mn net loss, and the annual report gives no sales figures for the app.
Daito Pharmaceutical is folding into a new joint venture to absorb Kyorin's generic drug business while telling lawmakers that three straight years of annual price cuts have made its dominant Parkinson's disease tablet impossible to produce at a profit.
Current holdings disclosed by tracked funds.